Literature DB >> 18690965

Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends.

Amalia M Issa1, Kathryn A Phillips, Stephanie Van Bebber, Hima G Nidamarthy, Karen E Lasser, Jennifer S Haas, Brian K Alldredge, Robert M Wachter, David W Bates.   

Abstract

There have been a number of highly publicized safety-based drug withdrawals in the United States in recent years. We conducted a review of drugs withdrawn since 1993 and examined trends in drug withdrawals. Our objective was to determine the frequency and characteristics of withdrawn drugs and trends since 1993, and to discuss the implications of the findings. We found that a mean of 1.5 drugs per year have been withdrawn since 1993, and that the number of withdrawals has not increased over time. However, some recent drug withdrawals have impacted large numbers of people. The rate of withdrawals alone is not an adequate measure of the status of drug safety in the US, and there is a serious dearth of data that can be used to examine the impact of drug withdrawals. Although drug withdrawals are an important issue to address, drug safety policies need to be developed within the broader context of drug safety and effectiveness. A comprehensive approach will be needed to address the improvement of drug safety. We propose improvements to the evidence base to increase drug safety and assess how new scientific evidence can be incorporated into drug safety efforts.

Entities:  

Mesh:

Year:  2007        PMID: 18690965     DOI: 10.2174/157488607781668855

Source DB:  PubMed          Journal:  Curr Drug Saf        ISSN: 1574-8863


  15 in total

1.  Pharmacovigilance and the null hypothesis: do we do much for public health?

Authors:  I Ralph Edwards; Ambrose Isah
Journal:  Drug Saf       Date:  2011-02-01       Impact factor: 5.606

Review 2.  In vitro testing for diagnosis of idiosyncratic adverse drug reactions: Implications for pathophysiology.

Authors:  Abdelbaset A Elzagallaai; Michael J Rieder
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

Review 3.  Key concepts of clinical trials: a narrative review.

Authors:  Craig A Umscheid; David J Margolis; Craig E Grossman
Journal:  Postgrad Med       Date:  2011-09       Impact factor: 3.840

Review 4.  Biomarkers of drug-induced liver injury.

Authors:  Mitchell R McGill; Hartmut Jaeschke
Journal:  Adv Pharmacol       Date:  2019-03-06

Review 5.  Animal models of drug-induced liver injury.

Authors:  Mitchell R McGill; Hartmut Jaeschke
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-09-03       Impact factor: 5.187

Review 6.  Biomarkers of drug-induced liver injury: progress and utility in research, medicine, and regulation.

Authors:  Mitchell R McGill; Hartmut Jaeschke
Journal:  Expert Rev Mol Diagn       Date:  2018-08-13       Impact factor: 5.225

Review 7.  QT interval prolongation among patients treated with angiogenesis inhibitors.

Authors:  Stephane Ederhy; Ariel Cohen; Ghislaine Dufaitre; Hassan Izzedine; Christophe Massard; Catherine Meuleman; Benjamin Besse; Emmanuelle Berthelot; Franck Boccara; Jean-Charles Soria
Journal:  Target Oncol       Date:  2009-05-06       Impact factor: 4.493

8.  Functional Module Connectivity Map (FMCM): a framework for searching repurposed drug compounds for systems treatment of cancer and an application to colorectal adenocarcinoma.

Authors:  Feng-Hsiang Chung; Yun-Ru Chiang; Ai-Lun Tseng; Yung-Chuan Sung; Jean Lu; Min-Chang Huang; Nianhan Ma; Hoong-Chien Lee
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

9.  Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.

Authors:  Agustin H Mohedas; You Wang; Caroline E Sanvitale; Peter Canning; Sungwoon Choi; Xuechao Xing; Alex N Bullock; Gregory D Cuny; Paul B Yu
Journal:  J Med Chem       Date:  2014-09-04       Impact factor: 7.446

10.  Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies.

Authors:  Anita J Chawla; Daniel S Mytelka; Stephan D McBride; Dave Nellesen; Benjamin R Elkins; Daniel E Ball; Anupama Kalsekar; Adrian Towse; Louis P Garrison
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-01-14       Impact factor: 2.890

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.